Skip to main content

Douglas Robert Andrew's Form 4 filing

Resmed Inc (RMD) · filed Nov 15, 2021

Accession no.
0001127602-21-029234
Filed
Nov 15, 2021
Trade date
Nov 11-15, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.17M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Douglas Robert AndrewCIK 0001352232Officer (President and COO ResMed Inc.)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 11, 2021ResMed Common StockFTax withholdingDisposed−945$259.47−$245,199.1521,266Direct
Nov 15, 2021ResMed Common StockMOption exerciseAcquired+8,000$58.24+$465,92029,266Direct
Nov 15, 2021ResMed Common StockSSaleDisposed−8,000$271.75−$2,174,00021,266Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2021ResMed Common StockMOption exerciseDisposed−8,000$0.00$094,098Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)